TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02685436

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole and domperidone
Description: wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
Study: NCT03449147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 15 mg BID
Description: Gefapixant 15 mg tablet administered orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg BID
Description: Gefapixant 45 mg tablet administered orally BID
Study: NCT02973022

Intervention type: OTHER
Intervention: CC&S
Description: Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC\&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
Study: NCT02725853

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-personalized practice
Description: arm exercise consisting of unrestricted whole arm movement
Study: NCT02929173

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allceram
Description: Pressed E-max coping veneered with E-max veneering system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid crown
Description: pressed Bio HPP coping veneered with visolign veneering system
Study: NCT01885871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond QS Nd:YAG Laser
Description: Up to 2 laser treatments delivered 6 weeks apart
Study: NCT01941043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01917032

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food
Description: 1 g orally on weekdays during 11 weeks
Study: NCT01941043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04215588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostasis Management System Plus
Description: Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activated Coagulation Timer System Plus
Description: The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.
Study: NCT03956056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Peptide Vaccine
Description: • Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: • Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for immune monitoring
Description: -Baseline, day 1, day 22, day 50, day 78, week 25, and week 73
Study: NCT00509392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seg. RF Ablation & ClosureFAST catheter
Description: Seg. RF Ablation \& ClosureFAST catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous Laser
Description: laser catheter
Study: NCT01917032

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04119310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar-thrust mobilization
Description: The intervention group will receive passive spinal rotational grade V thrust-mobilization, based on Maitland's approach. The intervention will be performed with the subject in right sidelying and left sidelying. The operator's palpating hand is placed over the L2-3 intervertebral space, and the other hand bends both legs of the participant up to the range at which the L2-3 midposition is found. The participant is then asked to straighten the lower leg and hook the upper leg over it with the upper leg's knee positioned over the side of the plinth. While the lower component is kept still, the participant's trunk is rotated until the hip starts to lift off from the plinth. The bottom hand and uppermost hand rest under a pillow and the chest wall, respectively. With the starting position settled, the operator stands behind the participant, takes up the slack within the spine and then provides a grade V thrust- mobilization while stabilizing the uppermost shoulder.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham thrust-mobilization
Description: Subjects are positioned in right sidelying. The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension passive range of motion without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
Study: NCT02537782

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac resynchronisation therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography
Study: NCT03602495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib 0.3g Bid orally, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
Study: NCT02537782

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Positron Emission Tomography
Study: NCT03602495

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo Bid orally, continuously.
Study: NCT02595970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.
Study: NCT02310932

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Living Intervention
Description: Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support.
Study: NCT04389476

Intervention type: OTHER
Intervention: Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)
Description: Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors.

Intervention type: OTHER
Intervention: Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)
Description: Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors.
Study: NCT02310932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living Intervention
Description: Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support.
Study: NCT03007407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive durvalumab (1500 mg IV infusion) on Day 1 for 4 cycles (in combination with tremelimumab). Beginning with Cycle 5 through Cycle 12, patients will receive durvalumab alone (1500 mg/IV infusion) on Day 1 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Following three doses of hypofractionated palliative radiation (Days -2, -1, and Day 0 prior to Cycle 1), patients will receive tremelimumab (75 mg IV infusion) on Day 1 for 4 cycles (in combination with durvalumab).
Study: NCT03960931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic rehabilitation
Description: Rehabilitation sessions using hydrophysiotherapy will occur in a pool of Grand Nancy Thermal, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land based physical activities
Description: Rehabilitation sessions on treadmill will occur at Physical Medicine and Rehabilitation Regional Institute (IRR), on the University Hospital's site, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking, where intensity of effort can be modulated by speed and inclination of treadmill. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation sessions will occur in private practices in which patients receive their habitual care (same physiotherapist). This care will be guided by prescription delivered by the neurologist. This prescription suggests to work on active and passive upper and lower limb stretching, on hip and shoulder dissociation, and balance control management on unstable ground.
Study: NCT03802812

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thin bronchoscope and VBN
Description: targeted washing at more adjacent TB lesion using thin bronchoscope and virtual bronchoscopic navigation system
Study: NCT01904539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obeticholic acid 10 mg
Description: Single dose OCA 10mg in each arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obeticholic acid 10 mg
Description: Single dose OCA 10mg in each arm
Study: NCT01952262

Intervention type: OTHER
Intervention: diaphragm ultrasound
Description: we'll perform diaphragm ultrasound in ICU critically ill patients
Study: NCT02368873

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Application of IPOM mesh
Study: NCT05241483

Intervention type: DIAGNOSTIC_TEST
Intervention: mesure valition
Description: Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems

Intervention type: DIAGNOSTIC_TEST
Intervention: mesure valition
Description: Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems

Intervention type: DIAGNOSTIC_TEST
Intervention: mesure valition
Description: Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems
Study: NCT02561416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
Study: NCT05241483

Intervention type: DIAGNOSTIC_TEST
Intervention: mesure valition
Description: Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems

Intervention type: DIAGNOSTIC_TEST
Intervention: mesure valition
Description: Possible diseases that may occur as a result of the patient's vital values with artificial intelligence systems
Study: NCT03461263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: phonophoresis treatment using pumpkin seeds oil
Description: phonophoresis treatment using pumpkin seeds oil
Study: NCT06557109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Popular Music
Description: A funky D mix version of a popular Turkish song
Study: NCT03589469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Description: intravenous infusion
Study: NCT03898843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal assisted therapy
Description: Patients of AAT group will leave their hospital bedroom to go in the session room, where they will meet a dog, who has come with his veterinary student master. Animal assisted therapy session will last at most 20 minutes, in which the patient is going to interact with the dog, pet him, play with him, etc.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nasal swab sampling
Description: All patients will have nasal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nasal swab sampling
Description: All patients will have nasal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAI-Y and POMS Questionnaires
Description: Before and after AAT or sham session, patients will answer State-Trait Anxiety Inventory Y (STAI-Y), Profile of Mood States (POMS) questionnaires.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STAI-Y and POMS Questionnaires
Description: Before and after AAT or sham session, patients will answer State-Trait Anxiety Inventory Y (STAI-Y), Profile of Mood States (POMS) questionnaires.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiological parameters measure
Description: Before and after AAT or sham session, blood pressure, heart rate dans respiratory rate will be measured.
Study: NCT05305703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical stretching
Description: Heating therapy for 10 minutes Passive stretching of neck muscles including Sub-occipital muscles, Trapezius upper boarder and Sternocleidomastoid muscle with 10 reps each

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soft tissue mobilization
Description: Heating therapy for 10 minutes Soft tissue mobilization for 8 minutes and trigger point release of sub-occiptal muscles with 5 repetitions each.
Study: NCT04628052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Music vs. No-Music
Study: NCT02688335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud9
Description: Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
Study: NCT00050011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants received Letrozole 2.5 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants received Letrozole 2.5 mg daily.
Study: NCT01462331

Intervention type: OTHER
Group type: OTHER
Intervention: Isomaltooligosaccharide (digestion-resistant carbohydrates)
Description: 12g/dose; three times a day
Study: NCT02785055

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Placement
Description: Thoracic Epidural Placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Placement
Description: Thoracic Epidural Placement
Study: NCT03898843

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiological parameters measure
Description: Before and after AAT or sham session, blood pressure, heart rate dans respiratory rate will be measured.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Description: Before and after AAT or sham session, pain will be evaluated thanks to VAS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Analog Scale (VAS)
Description: Before and after AAT or sham session, pain will be evaluated thanks to VAS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Event Scale - Revised (IES-R)
Description: Patients will answer IES-R questionnaire 3 months after AAT or sham session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of Event Scale - Revised (IES-R)
Description: Patients will answer IES-R questionnaire 3 months after AAT or sham session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: satisfaction questionnaire
Description: Patients of the AAT group will answer satisfaction questionnaire at the end of the AAT session and 3 months after AAT
Study: NCT02561416

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FibroQol
Description: Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.~Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.~Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).~Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV.
Study: NCT04924751

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided fine needle biopsy
Description: Under endoscopic ultrasound guidance, fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided fine needle biopsy
Description: Under endoscopic ultrasound guidance, fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions.
Study: NCT00084864

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: Given orally
Study: NCT01462331

Intervention type: OTHER
Group type: OTHER
Intervention: Isomaltooligosaccharide (digestion-resistant carbohydrates)
Description: 18g/dose, three times a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: 12g/dose, three times a day
Study: NCT02785055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.05%
Description: Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.05%
Description: Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone 0.01mg/mL
Description: Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone 0.01mg/mL
Description: Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
Study: NCT00234143

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin and Filgrastim
Description: Aranesp and Neupogen G-CSF (Neupogen) 300 mcg s.c. twice a week, 3-4 days apart and EPO (Aranesp) 500 mcg s.c. once every 2 weeks until week 24, titrate depending of response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin
Description: Aranesp EPO (Aranesp) 500 mcg s.c. once every 2 weeks until 24 weeks, titrate depending of response
Study: NCT02561416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU
Description: In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
Study: NCT03898843

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rectal swab sampling
Description: All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria